Skip to main content
Premium Trial:

Request an Annual Quote

Amersham, Thermo Electron, Europroteome, Phase-it, Agilent Technologies, Luminex

Premium

Amersham and Thermo Electron Collaborate on Proteomics Products

Amersham Biosciences of Piscataway, NJ, and Thermo Electron of Waltham, Mass., said last week they would jointly market and distribute proteomics products.

Initially, the two companies will co-market Amersham’s Ettan MALDI-ToF Pro mass spectrometer and Thermo Finnigan’s line of ion trap mass spectrometers.

Later, they plan to collaborate on developing instruments, software, and reagents for proteomics applications.

 

Europroteome Buys Bioinformatics Startup Phase-it

Europroteome of Henningsdorf, Germany, has acquired bioinformatics firm Phase-it Intelligent Solutions of Heidelberg, Germany, the company said last week.

The deal was approved by shareholders of both companies. Financial details were not disclosed.

Phase-it’s operations will stay in Heidelberg, and its collaboration with the German Cancer Research Center will continue. Europroteome aims to develop treatments and diagnostics for epithelial cancer, applying proteomics in its research.

 

Agilent Technologies and DiagnoSwiss to Develop Electrophoresis Apparatus

Agilent Technologies of Palo Alto, Calif., and DiagnoSwiss of Monthey, Switzerland, said they would collaborate to jointly develop solution-based electrophoresis technology for protein fractionation. The instrument would be used to separate proteins and peptides in complex mixtures according to their isoelecetric point. DiagnoSwiss develops biochips, focusing currently on polymer microchips with integrated microelectrodes.

 

Luminex Sees Revenues Shrink, Losses Grow in Q4

Luminex of Austin, Texas, last week reported growing losses for the fourth quarter of 2002.

Revenues for the quarter fell to $4 million from $6.2 million the year before. Net losses increased to $6.3 million, or $0.21 per share, compared to $3.7 million, or $0.13 million per share, in the fourth quarter of 2001.

Revenues for 2002 were $13 million, down from $20.9 million in 2001. Net losses soared to $24.3 million, or $0.83 per share, compared with $15.7 million, or $0.55 per share, the year before.

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.